DPP-4 inhibition is an important target for the T2DM treatment, providing increased GLP-1 concentration, with consequent increase of insulin secretion by pancreatic βcells and reduction of glucagon secretion from pancreatic α-cells, which in turn reduces hepatic glucose output[6]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.